XBiotech Inc. (NASDAQ:XBIT - Get Free Report) shares crossed above its 50 day moving average during trading on Tuesday . The stock has a 50 day moving average of $3.23 and traded as high as $3.27. XBiotech shares last traded at $3.13, with a volume of 56,497 shares trading hands.
XBiotech Stock Down 0.3 %
The company has a fifty day moving average of $3.22 and a 200 day moving average of $5.03. The company has a market cap of $99.70 million, a P/E ratio of -3.03 and a beta of 1.28.
XBiotech (NASDAQ:XBIT - Get Free Report) last posted its quarterly earnings data on Tuesday, March 18th. The biopharmaceutical company reported ($0.34) earnings per share (EPS) for the quarter.
Institutional Inflows and Outflows
A number of hedge funds and other institutional investors have recently made changes to their positions in the business. Deutsche Bank AG acquired a new stake in shares of XBiotech during the 4th quarter worth approximately $120,000. Bank of America Corp DE lifted its position in XBiotech by 42.0% in the fourth quarter. Bank of America Corp DE now owns 19,888 shares of the biopharmaceutical company's stock valued at $79,000 after purchasing an additional 5,887 shares during the period. Northern Trust Corp boosted its holdings in XBiotech by 15.2% during the fourth quarter. Northern Trust Corp now owns 211,476 shares of the biopharmaceutical company's stock worth $835,000 after buying an additional 27,909 shares in the last quarter. Barclays PLC raised its position in XBiotech by 13.9% during the fourth quarter. Barclays PLC now owns 30,004 shares of the biopharmaceutical company's stock worth $119,000 after acquiring an additional 3,661 shares during the last quarter. Finally, JPMorgan Chase & Co. lifted its stake in shares of XBiotech by 68.2% during the fourth quarter. JPMorgan Chase & Co. now owns 14,624 shares of the biopharmaceutical company's stock valued at $58,000 after buying an additional 5,930 shares during the period. Hedge funds and other institutional investors own 55.70% of the company's stock.
XBiotech Company Profile
(
Get Free Report)
XBiotech Inc, a biopharmaceutical company, discovers, develops, and commercializes True Human monoclonal antibodies for treating various diseases. The company focuses on developing a pipeline of product candidates targeting both inflammatory and infectious diseases. It is also developing interleukin-1 alpha therapies to treat variety of medical conditions, such as cancer, stroke, heart attack, or arthritis; and mediates tissue breakdown, angiogenesis, the formation of blood clots, malaise, muscle wasting, and inflammation.
See Also
Before you consider XBiotech, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and XBiotech wasn't on the list.
While XBiotech currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
